Leap Enterprise Value Multiple from 2010 to 2024
| LPTX Stock | USD 3.19 0.02 0.63% |
Enterprise Value Multiple | First Reported 2010-12-31 | Previous Quarter (0.16) | Current Value (0.17) | Quarterly Volatility 2.4575849 |
Check Leap Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Leap main balance sheet or income statement drivers, such as Depreciation And Amortization of 728.7 K, Interest Expense of 4.8 K or Selling General Administrative of 8.7 M, as well as many exotic indicators such as Price To Sales Ratio of 110, Dividend Yield of 0.0 or PTB Ratio of 1.41. Leap financial statements analysis is a perfect complement when working with Leap Therapeutics Valuation or Volatility modules.
Leap | Enterprise Value Multiple |
Latest Leap Therapeutics' Enterprise Value Multiple Growth Pattern
Below is the plot of the Enterprise Value Multiple of Leap Therapeutics over the last few years. It is Leap Therapeutics' Enterprise Value Multiple historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Leap Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Multiple | 10 Years Trend |
|
Enterprise Value Multiple |
| Timeline |
Leap Enterprise Value Multiple Regression Statistics
| Arithmetic Mean | (2.98) | |
| Geometric Mean | 1.64 | |
| Coefficient Of Variation | (82.37) | |
| Mean Deviation | 2.11 | |
| Median | (2.99) | |
| Standard Deviation | 2.46 | |
| Sample Variance | 6.04 | |
| Range | 6.4425 | |
| R-Value | 0.80 | |
| Mean Square Error | 2.30 | |
| R-Squared | 0.65 | |
| Significance | 0.0003 | |
| Slope | 0.44 | |
| Total Sum of Squares | 84.56 |
Leap Enterprise Value Multiple History
About Leap Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Leap Therapeutics income statement, its balance sheet, and the statement of cash flows. Leap Therapeutics investors use historical funamental indicators, such as Leap Therapeutics's Enterprise Value Multiple, to determine how well the company is positioned to perform in the future. Although Leap Therapeutics investors may use each financial statement separately, they are all related. The changes in Leap Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Leap Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Leap Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Leap Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Multiple | (0.16) | (0.17) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Leap Therapeutics Correlation against competitors. For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Leap Stock analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Leap Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Leap Therapeutics. If investors know Leap will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Leap Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.98) | Revenue Per Share 0.003 | Return On Assets (0.75) | Return On Equity (1.37) |
The market value of Leap Therapeutics is measured differently than its book value, which is the value of Leap that is recorded on the company's balance sheet. Investors also form their own opinion of Leap Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Leap Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Leap Therapeutics' market value can be influenced by many factors that don't directly affect Leap Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Leap Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Leap Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Leap Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.